echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Increase and decrease of net profit of Listed Pharmaceutical Enterprises: nearly 90% kept rising; 5 pharmaceutical enterprises made more than 100 million yuan

    Increase and decrease of net profit of Listed Pharmaceutical Enterprises: nearly 90% kept rising; 5 pharmaceutical enterprises made more than 100 million yuan

    • Last Update: 2018-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the data of China Business Industry Research Institute, by the end of April 2018, the number of Enterprises above Designated Size in China's pharmaceutical industry had reached 7486, including 1288 loss making enterprises and 17.2% loss making enterprises, down 1.39 percentage points from last month The total loss of the pharmaceutical industry in the first four months of 2018 was 5.31 billion yuan, up 36.9% year on year According to the public data, from January to April 2017, the total accumulated profit of the pharmaceutical industry was 97.6 billion yuan, up 14.50% year on year, down 1.1 percentage points from the same period last year Note: the data is from China Business Industry Research Institute for reference From January to April 2018, the main business income of China's pharmaceutical industry reached 826.75 billion yuan, a year-on-year increase of 14.90% The total profit of the industry reached 98.79 billion yuan, a year-on-year increase of 16.45 note: the data is from China Business Industry Research Institute for reference ▍ listed pharmaceutical companies should be more optimistic than the overall situation of the industry, and the year will be more than half With the approach of the release window of the semi annual report, more and more pharmaceutical companies have released the performance forecast for the first half of 2018, which is really "the tide is ebbing, and who knows who is swimming naked" The first performance report of some pharmaceutical companies shows a change in performance, while some pharmaceutical companies maintain a rapid growth As of yesterday (June 27), 89 or nearly 90 (nearly 30%) pharmaceutical enterprises in China have released the half year performance forecast in 2018, of which 83 have made profit, 5 have made loss, and 1 is uncertain On the loss side, less than 6% According to the increase and decrease of the net profit of 89 listed pharmaceutical enterprises, 10 enterprises decreased, accounting for 11%, and nearly 90% enterprises kept rising How do five pharmaceutical companies make more than one billion yuan and one of them makes 2.5 billion yuan? Among the more than 80 profitable enterprises are XinHeCheng, xinlitai and Lepu medical The net profits of five pharmaceutical enterprises of Kelun pharmaceutical and Ruikang pharmaceutical are more than 500 million yuan Among them, the performance of new Hecheng has increased about three times year-on-year, making about 2.5 billion yuan The company is a state-level high-tech enterprise mainly engaged in the production and sale of nutriments, flavors and fragrances, new polymer materials and APIs After development and accumulation, the company has good market reputation and honor in the global fine chemical industry It is one of the top ten feed additive brands in China and one of the largest vitamin feed additive enterprises in China, laying a solid foundation for the company's development In 2017, XinHeCheng has achieved a net profit of more than 1.7 billion yuan, with a net interest rate fund of 30%, a year-on-year increase of 41% In 2018, when the price of vitamins increased significantly, the net profit increased significantly In the first quarter of 2018, the company achieved a revenue of 3 billion yuan, a year-on-year increase of nearly 130%, and a net profit of nearly 1.5 billion yuan, a year-on-year increase of more than five times It can be seen that it is highly possible for enterprises to achieve 2.227-2.520 billion in the first half of the year ※ based on the core of cardiovascular field, xinlitai xinlitai has actively extended to the fields of hypoglycemia, anti-tumor and orthopedics, built three innovative main lines of high-end prescription medicine, innovative biological medicine and medical device industry chain, and improved the layout and planning of R & D pipeline In 2017, the company achieved an operating revenue of more than 4.1 billion yuan, a net profit of 1.45 billion yuan, and a net profit level of 35% In the first quarter of 2018, the company achieved a revenue of 1.1 billion yuan and a net profit of 410 million yuan Accordingly, xinlitai expects to achieve a net profit of 767-840 million in the first half of 2018 Based on the main business of medical device business segment, Lepu medical music continues to consolidate the advantageous position of cardiovascular medical device industry, continue to promote the market application and new product research and development of high-end interventional devices, diagnostic reagents and devices in cardiovascular field, and realize the continuous and stable growth of this business segment In 2017, it achieved an operating revenue of 4.5 billion yuan, a net profit of nearly 900 million yuan, and a net interest rate of 20% In the first quarter of 2018, it achieved an operating revenue of 1.4 billion yuan, a year-on-year increase of nearly 40%, and a net profit of 300 million yuan It is estimated that the company's business will accelerate in the second quarter, and it is expected to achieve a net profit of 700-800 million yuan * Kelun pharmaceutical is the leading enterprise in China's large infusion market, accounting for more than 15% of China's market share In 2017, Kelun pharmaceutical achieved an operating revenue of 11.435 billion yuan, of which nearly 70% was from the large infusion business The company actively seeks transformation, and the proportion of non infusion income is greatly increased The non infusion income is close to 4 billion yuan, with a year-on-year growth of nearly 70% In 2017, the company realized a net profit of 748 million yuan, an increase of nearly 30% year on year In the first quarter of 2018, the company has realized an operating revenue of nearly 4 billion yuan, a year-on-year increase of nearly 60%, and a net profit of nearly 400 million yuan, a year-on-year nearly double growth * Ruikang pharmaceutical Ruikang pharmaceutical is a regional pharmaceutical company based in Shandong Province and spreading to the whole country Perfect sales network, strong terminal direct coverage, perfect sales network, strong terminal direct coverage has been one of the company's outstanding core competitive advantages At present, the company has copied the direct marketing model of Shandong Province in all provinces of China, controlled the sales channels of terminal medical institutions, and built a national channel platform At present, through holding companies in more than 20 provinces and cities, direct marketing channels have been built nationwide In 2017, the annual operating revenue was 23 billion yuan, and the net profit attributable to the shareholders of the listed company was more than 1 billion yuan In the first quarter of 2018, the operating revenue exceeded 7 billion yuan, a year-on-year increase of more than 40%, and the net profit was nearly 300 million yuan Therefore, the company expects to achieve a net profit of 500-600 million yuan in the semi annual report Among the remaining 70 profit-making enterprises, only Haixiang Hengkang Medical Co., Ltd and Huatong Medical Co., Ltd are the enterprises that are expected to decrease or slightly decrease; the remaining 75 enterprises are all expected to increase, slightly increase or continue to gain The specific situation is shown in the following table: ▍ it will be paid back sooner or later if you come out and mix There are also companies with a big loss of 650 million Shanghai Laishi is one of the most stock speculating companies in China's listed companies, none of them In the first two years, when the stock market was good, the enterprises made billions by stock speculation, bringing several times the net profit of the pharmaceutical business In those years, the real business income of Shanghai Laishi was no more than 2 billion yuan, which could realize a net profit of more than 1 billion yuan The level of net interest rate was the highest in the industry, and at the same time, it also created a blood product enterprise with a market value of 100 billion yuan However, Fengshui turns around, and the stock market is not good in the past two years Shanghai Laishi's shares are losing money, and the range is still expanding In the first quarter of 2018, Shanghai Laishi, which made a lot of money from stock speculation, lost nearly 700 million yuan Although the loss can be narrowed through its main business in the semi annual report, it is also expected to lose about 600 million yuan However, it should be noted that the half year performance forecast issued by Shanghai Laishi was at the end of April, and there were more than 3000 points in the market at that time The sharp drop in recent days is estimated to make its performance worse, which is likely to be much more loss than the original forecast.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.